药学学报, 2022, 57(5): 1361-1366
引用本文:
王海临, 周雯敏, 扶佳俐, 叶阳娇, 扈新, 高慧林, 张建业. 蟾毒灵抑制人前列腺癌PC3细胞迁移侵袭的机制研究[J]. 药学学报, 2022, 57(5): 1361-1366.
WANG Hai-lin, ZHOU Wen-min, FU Jia-li, YE Yang-jiao, HU Xin, GAO Hui-lin, ZHANG Jian-ye. Research on the mechanism of bufalin inhibiting migration and invasion of human prostate cancer PC3 cells[J]. Acta Pharmaceutica Sinica, 2022, 57(5): 1361-1366.

蟾毒灵抑制人前列腺癌PC3细胞迁移侵袭的机制研究
王海临1, 周雯敏2, 扶佳俐2, 叶阳娇2, 扈新1, 高慧林1, 张建业2*
1. 巴彦淖尔市医院泌尿外科, 内蒙古自治区 巴彦淖尔 015000;
2. 广州医科大学药学院, 广东省分子靶标与临床药理学重点实验室, 广东 广州 511436
摘要:
本研究主要探讨了蟾毒灵(bufalin)对人前列腺癌PC3细胞的体外增殖、迁移和侵袭的抑制能力,初步探讨蟾毒灵抑制上皮-间充质转化(epithelial-mesenchymal transformation,EMT)过程的分子机制。采用MTT法评价PC3细胞活力;划痕和Transwell实验用于检测细胞的迁移和侵袭能力;采用Western blot实验检测EMT和整合素家族蛋白的表达情况。结果显示,蟾毒灵对人前列腺癌PC3细胞的半数抑制浓度值为0.26 ±0.03 μmol·L-1,蟾毒灵处理后,PC3细胞的迁移速度变慢(P<0.05),穿过微孔滤膜的PC3细胞数量减少(P<0.05),这表明蟾毒灵能够浓度依赖性地抑制PC3细胞的增殖、迁移与侵袭能力。本研究发现蟾毒灵可以影响EMT相关蛋白的表达,包括E-钙黏附素(E-cadherin)的上调以及N-钙黏附素(N-cadherin)、β-连环蛋白(β-catenin)、基质金属蛋白酶9(MMP9)、基质金属蛋白酶2(MMP2)、癌基因c-myc、锌指转录因子Snail的下调;蟾毒灵还可以抑制整合素家族蛋白的表达,包括整合素α2(ITGA2)、整合素β1(ITGB1)、整合素β3(ITGB3)、整合素β5(ITGB5)、Yes相关蛋白/转录共激活因子PDZ结合基序(YAP/TAZ)和整合素连接激酶(ILK)。此外,蟾毒灵还可抑制磷酸化局部黏着斑激酶(p-FAK)/局部黏着斑激酶(FAK)、磷酸化类固醇受体辅激活因子(p-Src)/类固醇受体辅激活因子(Src)、磷酸化蛋白激酶B (p-Akt)/蛋白激酶B (Akt)的蛋白表达水平,上述研究结果表明,蟾毒灵可能通过FAK/Src/磷酸肌醇3-激酶(PI3K)/Akt通路抑制前列腺癌PC3细胞的增殖、转移和侵袭能力。因此,蟾毒灵为前列腺癌治疗药物的开发提供一定的参考价值。
关键词:    蟾毒灵      前列腺癌      抗肿瘤      增殖      转移     
Research on the mechanism of bufalin inhibiting migration and invasion of human prostate cancer PC3 cells
WANG Hai-lin1, ZHOU Wen-min2, FU Jia-li2, YE Yang-jiao2, HU Xin1, GAO Hui-lin1, ZHANG Jian-ye2*
1. Department of Urology, Bayannur Hospital, Bayannur 015000, China;
2. Guangdong Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmacy, Guangzhou Medical University, Guangzhou 511436, China
Abstract:
In this study, we investigated the inhibitory effects of bufalin on proliferation, migration and invasion of PC3 cells in vitro, and preliminarily explored the molecular mechanism of epithelial-mesenchymal transformation (EMT) inhibited by bufalin. The viability of PC3 cells was evaluated by MTT assay, and the migration and invasion abilities of PC3 cells were detected by wound healing and Transwell assay. Western blot was used to detect the expression of EMT and integrin family proteins. The results showed that the half maximal inhibitory concentration (IC50) value of bufalin against PC3 cells was 0.26 ±0.03 μmol·L-1. After bufalin treatment, the migration rate of PC3 cells slowed down (P < 0.05), the number of PC3 cells passing through the microporous membrane decreased (P < 0.05), which indicated that bufalin could inhibit the proliferation, migration and invasion
of PC3 cells in a concentration-dependent manner. We found that bufalin could affect the expression of EMT-related proteins,including up-regulation of E-cadherin and down-regulation of N-cadherin, β-catenin, matrix metalloproteinase 9 (MMP9), matrix metalloproteinase 2 (MMP2), c-myc and Snail. Bufalin also inhibited the expression of integrin family proteins, including integrin α2 (ITGA2), integrin β1 (ITGB1), integrin β3 (ITGB3), integrin β5 (ITGB5), Yes-associated protein/transcriptional coactivator with a PDZ-binding motif (YAP/TAZ) and integrin-linked kinase (ILK). In addition, bufalin could also inhibit the protein expression level of phospho-focal adhesion kinase (p-FAK)/FAK, phospho-steroid receptor coactivator (p-Src)/Src and phospho-protein kinase B (p-Akt)/Akt. These results suggested that bufalin might inhibit the proliferation, metastasis and invasion of prostate cancer PC3 cells through the FAK/Src/phosphoinositide 3-kinase (PI3K)/Akt pathway. Therefore, bufalin provides reference value for the development of therapeutic drugs for prostate cancer.
Key words:    bufalin    prostate cancer    anti-tumor    proliferation    metastasis   
收稿日期: 2021-11-15
DOI: 10.16438/j.0513-4870.2021-1643
基金项目: 国家自然科学基金资助项目(U1903126);2020年国家级大学生创新创业训练计划(202010570032).
通讯作者: 张建业,Tel:86-20-37103631,E-mail:jianyez@163.com
Email: jianyez@163.com
相关功能
PDF(546KB) Free
打印本文
0
作者相关文章
王海临  在本刊中的所有文章
周雯敏  在本刊中的所有文章
扶佳俐  在本刊中的所有文章
叶阳娇  在本刊中的所有文章
扈新  在本刊中的所有文章
高慧林  在本刊中的所有文章
张建业  在本刊中的所有文章

参考文献:
[1] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71:209-249.
[2] Xue MX, Yue G, Guo SJ, et al. The mechanism of androgen independent signaling pathway in castration-resistant prostate cancer and the research progress on related drugs[J]. Acta Pharm Sin (药学学报), 2021, 56:21-28.
[3] Evans AJ. Treatment effects in prostate cancer[J]. Mod Pathol, 2018, 31:110-121.
[4] Gîngu C, Heidenreich A, Andresanu A, et al. Treatment of the primary in metastatic prostate cancer[J]. Curr Opin Urol, 2020, 30:566-575.
[5] Xiang YN, Guo ZM, Zhu PF, et al. Traditional Chinese medicine as a cancer treatment:modern perspectives of ancient but advanced science[J]. Cancer Med, 2019, 8:1958-1975.
[6] Yin PH, Liu X, Qiu YY, et al. Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers:new hope for cancer patients[J]. Asian Pac J Cancer Prev, 2012, 13:5339-5343.
[7] Lan YL, Lou JC, Jiang XW, et al. A research update on the anticancer effects of bufalin and its derivatives[J]. Oncol Lett, 2019, 17:3635-3640.
[8] Wang J, Xia Y, Zuo QS, et al. Molecular mechanisms underlying the antimetastatic activity of bufalin[J]. Mol Clin Oncol, 2018, 8:631-636.
[9] Li JJ, Guo QR, Lei XP, et al. Pristimerin induces apoptosis and inhibits proliferation, migration in H1299 lung cancer cells[J]. J Cancer, 2020, 11:6348-6355.
[10] Wei MY, Li JJ, Qiu JH, et al. Costunolide induces apoptosis and inhibits migration and invasion in H1299 lung cancer cells[J]. Oncol Rep, 2020, 43:1986-1994.
[11] Huang WJ, Yan YY, Liu Y, et al. Exosomes with low miR-34c-3p expression promote invasion and migration of non-small cell lung cancer by upregulating integrin α2β1[J]. Signal Transduct Target Ther, 2020, 5:39.
[12] Li L, Dong Z, Shi PF, et al. Bruceine D inhibits cell proliferation through downregulating LINC01667/microRNA-138-5p/cyclin E1 axis in gastric cancer[J]. Front Pharmacol, 2020, 11:584960.
[13] Wang J, Cai H, Xia Y, et al. Bufalin inhibits gastric cancer invasion and metastasis by down-regulating Wnt/ASCL2 expression[J]. Oncotarget, 2018, 9:23320-23333.
[14] Qian LQ, Su HY, Wang G, et al. Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer[J]. J Cancer, 2020, 11:3114-3123.
[15] Liu X, Zhou YY, Peng JM, et al. Silencing c-Myc enhances the antitumor activity of bufalin by suppressing the HIF-1α/SDF-1/CXCR4 pathway in pancreatic cancer cells[J]. Front Pharmacol, 2020, 11:495.
[16] Loh CY, Chai JY, Tang TF, et al. The E-cadherin and N-cadherin switch in epithelial-to-mesenchymal transition:signaling, therapeutic implications, and challenges[J]. Cells, 2019, 8:1118.
[17] Patel S, Alam A, Pant R, et al. Wnt signaling and its significance within the tumor microenvironment:novel therapeutic insights[J]. Front Immunol, 2019, 10:2872.
[18] Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases[J]. Int J Mol Sci, 2020, 21:9739.
[19] Rebello RJ, Pearson RB, Hannan RD, et al. Therapeutic approaches targeting MYC-driven prostate cancer[J]. Genes (Basel), 2017, 8:71.
[20] Smith BN, Odero-Marah VA. The role of Snail in prostate cancer[J]. Cell Adh Migr, 2012, 6:433-441.
[21] Zhang YX, Shao RG, He HW. Regulation of integrin gene expression[J]. Acta Pharm Sin (药学学报), 2017, 52:1647-1651.
[22] Juan-Rivera MC, Martínez-Ferrer M. Integrin inhibitors in prostate cancer[J]. Cancers (Basel), 2018, 10:44.
[23] Coffey K. Targeting the Hippo pathway in prostate cancer:what's new?[J]. Cancers (Basel), 2021, 13:611.
[24] Zheng CC, Hu HF, Hong P, et al. Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer[J]. Am J Cancer Res, 2019, 9:186-197.
[25] Wu CY, You J, Fu JJ, et al. Phosphatidylinositol 3-kinase/Akt mediates integrin signaling to control RNA polymerase I transcriptional activity[J]. Mol Cell Biol, 2016, 36:1555-1568.
[26] Huang YL, Chu YL, Ho CT, et al. Antcin K, an active triterpenoid from the fruiting bodies of basswood-cultivated Antrodia cinnamomea, inhibits metastasis via suppression of integrin-mediated adhesion, migration, and invasion in human hepatoma cells[J]. J Agric Food Chem, 2015, 63:4561-4569.
相关文献:
1.余伟, 董金娇, 朱昕悦, 杨侃, 刘振明, 乔晓强, 宋亚丽.靛红衍生物类棕榈酰基转移酶抑制剂的设计、合成及抗肿瘤活性研究[J]. 药学学报, 2022,57(4): 1073-1079
2.刘建兵, 戚梦, 李巧琪, 李佳欢, 胡开辉, 林文雄, 傅俊生.虫草素抑制胰腺癌干细胞增殖及转移的机制研究[J]. 药学学报, 2017,52(9): 1404-1409
3.邹翩, 裴江鸿, 石卫, 陈莉.基于GSTπ的抗肿瘤药物研究进展[J]. 药学学报, 2016,51(2): 241-247
4.唐克, 杨瀚泽, 李燕, 田康, 李超, 周琬琪, 牛非, 冯志强, 陈晓光.小分子靶向化合物T03的抗肿瘤作用及机制研究[J]. 药学学报, 2014,49(6): 861-868
5.吴 旭,高 波,杨 健,边宝林,王宏洁.华蟾素注射液多肽成分体外抗肿瘤活性研究[J]. 药学学报, 2012,47(6): 822-826
6.徐嵩;徐世平;李兰敏;.取代4-苯乙烯基香豆素的合成及其抗肿瘤活性[J]. 药学学报, 2001,36(4): 269-273
7.刘秀均;李毅;甄永苏;.博安霉素对小鼠结肠癌及其肝转移的抑制作用[J]. 药学学报, 2001,36(1): 14-18
8.徐嵩;徐世平;李兰敏.6-或7-(取代苯乙烯基)香豆素类化合物的合成及其抗癌活性的研究[J]. 药学学报, 2000,35(2): 103-107
9.颜春洪;韩锐.异黄酮genistein对小鼠恶性黑色瘤转移的实验性治疗[J]. 药学学报, 1999,34(11): 814-817
10.施波;李兰敏;尤胜权;徐世平;韩锐.维A类化合物4-APR抑制肿瘤侵袭、转移的作用[J]. 药学学报, 1997,32(1): 33-37
11.刘建国;江敏;徐琳娜;甄永苏.二甲胺四环素增强博安霉素的抗肿瘤转移作用[J]. 药学学报, 1995,30(9): 668-673
12.强文安;刘锦蓉;王浴生;雷幼导.多抗甲素抗肿瘤转移作用及其机理[J]. 药学学报, 1994,29(5): 340-345